CD30 expression and survival in extranodal NK/T-cell lymphoma: a systematic review and meta-analysis

Zihang Chen, Pujun Guan, Tong Shan, Yunxia Ye, Limin Gao, Zhi Wang, Sha Zhao, Wenyan Zhang, Li Zhang _, Ling Pan and Weiping Liu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:16547-16556. https://doi.org/10.18632/oncotarget.24044

Metrics: PDF 1772 views  |   HTML 2787 views  |   ?  


Zihang Chen1,3,*, Pujun Guan2,3,*, Tong Shan4, Yunxia Ye1, Limin Gao1, Zhi Wang1, Sha Zhao1, Wenyan Zhang1, Li Zhang3, Ling Pan3 and Weiping Liu1

1Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

2Huaxi Magnetic Resonance Research Center, Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

3Department of Hematology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China

4Institute of Public Health, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA

*These authors contributed equally to this work

Correspondence to:

Li Zhang, email: [email protected]

Weiping Liu, email: [email protected]

Keywords: CD30; extranodal natural killer/T-cell lymphoma; prognostic value; meta-analysis

Received: July 13, 2017     Accepted: January 02, 2018     Epub: January 08, 2018     Published: March 27, 2018


Background: The paradoxical reports about the prognostic value of the CD30 expression in extranodal NK/T-cell lymphoma (ENKTL) have restricted its further applications in clinical practice. To identify the common effects and the variation, we conducted this systematic review and meta-analysis.

Methods: PubMed, MEDLINE, Embase, and Web of Science were searched between January 1975 and 31 January 2017. The pooled hazard ratio was used to estimate the effect of the CD30 expression on overall survival. Bias was assessed by prespecified criteria referring to Reporting Recommendations for Tumor Marker Prognostic Studies and Newcastle-Ottawa Scale.

Results: Ten retrospective cohort studies with 310 patients are included. CD30 is associated with better overall survival significantly (HR 0.71, 95% CI 0.51 to 0.99, I2 = 0%). A greater effect is observed among studies including participants predominant in regional involvement (HR 0.31, 95%CI 0.13 to 0.76, I2 = 0%) compared with those in systemic involvement.

Conclusions: This study indicates that the CD30 expression is significantly associated with better prognosis in ENKTL, especially for patients with regional lymphoma involvement.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24044